Multikinase inhibitor treatment in thyroid cancer
Thyroid cancer is the most common endocrine malignancy. Most thyroid cancer types
respond well to conventional treatment consisting of surgery and radioactive iodine (RAI) …
respond well to conventional treatment consisting of surgery and radioactive iodine (RAI) …
[HTML][HTML] Multikinase inhibitors in thyroid cancer: timing of targeted therapy
In the 9 years since the publication of our 2011 review of targeted treatment of thyroid cancer
with multikinase inhibitors, much has changed in the landscape of this heterogeneous …
with multikinase inhibitors, much has changed in the landscape of this heterogeneous …
Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer: treatment optimization for maximum clinical benefit
LJ Wirth, C Durante, DJ Topliss, E Winquist… - The …, 2022 - academic.oup.com
Background Lenvatinib is a multitargeted tyrosine kinase inhibitor approved for treating
patients with locally recurrent or metastatic progressive radioiodine-refractory differentiated …
patients with locally recurrent or metastatic progressive radioiodine-refractory differentiated …
Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib
MH Taylor, S Takahashi, J Capdevila, M Tahara… - Thyroid, 2021 - liebertpub.com
Background: Radioiodine-refractory differentiated thyroid cancer (RR-DTC) has a low 10-
year patient-survival rate and is challenging to treat. Lenvatinib is a multikinase inhibitor …
year patient-survival rate and is challenging to treat. Lenvatinib is a multikinase inhibitor …
Safety and effectiveness of lenvatinib in 594 patients with unresectable thyroid cancer in an all-case post-marketing observational study in Japan
S Takahashi, M Tahara, K Ito, M Tori, N Kiyota… - Advances in …, 2020 - Springer
Introduction Lenvatinib is approved in Japan for treating patients with all histological
subtypes of unresectable thyroid cancer, including differentiated thyroid cancer (DTC) …
subtypes of unresectable thyroid cancer, including differentiated thyroid cancer (DTC) …
Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: a multicenter study in Korea
Background: Lenvatinib, an oral multikinase inhibitor, is the latest addition to the treatment
options for radioactive iodine (RAI)-refractory progressive differentiated thyroid carcinoma …
options for radioactive iodine (RAI)-refractory progressive differentiated thyroid carcinoma …
Clinical indications for treatment with multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer
N Fukuda, S Takahashi - Cancers, 2021 - mdpi.com
Simple Summary Differentiated thyroid cancer generally has an indolent, slow-growing
nature. The disease gradually progresses in some of the patients and can ultimately develop …
nature. The disease gradually progresses in some of the patients and can ultimately develop …
Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global …
N Kiyota, M Tahara, B Robinson, M Schlumberger… - Cancer, 2022 - Wiley Online Library
Background Radioiodine‐refractory differentiated thyroid cancer (RAI‐R DTC) is an
aggressive form of thyroid cancer. Lenvatinib is a multikinase inhibitor approved for …
aggressive form of thyroid cancer. Lenvatinib is a multikinase inhibitor approved for …
Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis
T Oba, T Chino, A Soma, T Shimizu, M Ono, T Ito… - Endocrine …, 2020 - jstage.jst.go.jp
The tyrosine kinase inhibitors (TKIs) sorafenib, lenvatinib, vandetanib, and cabozantinib are
currently used for thyroid cancer treatment; however, the differences in their clinical efficacy …
currently used for thyroid cancer treatment; however, the differences in their clinical efficacy …
Nephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: an update
A Nervo, F Retta, A Ragni, A Piovesan, A Mella… - Critical Reviews in …, 2021 - Elsevier
Over the past decade, the prognosis of advanced thyroid cancer (TC) patients has
dramatically improved thanks to the introduction of tyrosine kinase inhibitors (TKIs). Despite …
dramatically improved thanks to the introduction of tyrosine kinase inhibitors (TKIs). Despite …